A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 3, 2012

AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial

Read more
Dec 22, 2011

AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial

Read more
Dec 21, 2011

Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trialfor Seasonal Flu Vaccine ASP7374

Read more
Dec 21, 2011

Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL® DosePro® Effective March 31, 2012

SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...

Read more
Dec 12, 2011

Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trialfor Seasonal Flu Vaccine ASP7374

Read more

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts